{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T04:03:29Z","timestamp":1743307409372,"version":"3.40.3"},"reference-count":39,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025,3,28]]},"DOI":"10.3960\/jslrt.24064","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T22:06:31Z","timestamp":1743113191000},"page":"40-48","source":"Crossref","is-referenced-by-count":0,"title":["Poor outcome of older patients with diffuse large B-cell lymphoma after progression"],"prefix":"10.3960","volume":"65","author":[{"given":"Hiroyuki","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuki","family":"Hirose","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuto","family":"Hibino","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Tokunaga","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Department of Hematology and Clinical Immunology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021; 384: 842-858.","DOI":"10.1056\/NEJMra2027612"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Philip T, Guglielmi C, Hagenbeek A <i>et al.<\/i> Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995; 333: 1540-1545.","DOI":"10.1056\/NEJM199512073332305"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Gisselbrecht C, Glass B, Mounier N <i>et al.<\/i> Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28: 4184-4190.","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Yamauchi N, Maruyama D. Current treatment approach and future perspectives in B cell lymphoma. Int J Hematol. 2024 [Epub ahead of print]. https:\/\/doi.org\/","DOI":"10.1007\/s12185-024-03879-w"},{"key":"5","unstructured":"5 Swerdlow S, Campo E, Harris N, <i>et al.<\/i> WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed, Lyon, IARC Press. 2017."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Hans CP, Weisenburger DD, Greiner TC <i>et al.<\/i> Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103: 275-282.","DOI":"10.1182\/blood-2003-05-1545"},{"key":"7","unstructured":"7 Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin\u2019s Disease Staging Classification. Cancer Res. 1971; 31: 1860-1861."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 . A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993; 329: 987-994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013; 48: 452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Di M, Huntington SF, Olszewski AJ. Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients. Oncologist. 2021; 26: 120-132.","DOI":"10.1002\/onco.13610"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Akimoto M, Miyazaki T, Takahashi H <i>et al.<\/i> Comparison of standardized prophylactic high-dose and intrathecal methotrexate for DLBCL with a high risk of CNS relapse. Int J Hematol. 2024; 119: 164-172.","DOI":"10.1007\/s12185-023-03700-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Camus V, Belot A, Oberic L <i>et al.<\/i> Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial. Blood Adv. 2022; 6: 6169-6179.","DOI":"10.1182\/bloodadvances.2022007609"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Tucci A, Masina L, Luminari S. Curative intent therapy for DLBCL in the elderly. Leuk Lymphoma. 2024; 65: 560-569.","DOI":"10.1080\/10428194.2024.2302323"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Wallace DS, Loh KP, Casulo C. How I treat older patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2025; 145: 277-289.","DOI":"10.1182\/blood.2024024788"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Pham TM, Quy PN, Amin K <i>et al.<\/i> Average lifespan shortened due to Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and leukemia in Japan, 1990\u20132015. Leuk Lymphoma. 2022; 63: 2084-2093.","DOI":"10.1080\/10428194.2022.2064990"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Nguyen PT, Hori M, Matsuda T, Katanoda K. Cancer prevalence projections in Japan and decomposition analysis of changes in cancer burden, 2020\u20132050: A statistical modeling study. Cancer Epidemiol Biomarkers Prev. 2023; 32: 1756-1770.","DOI":"10.1158\/1055-9965.EPI-23-0754"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Jantunen E, Canals C, Rambaldi A <i>et al.<\/i> Autologous stem cell transplantation in elderly patients (&gt; or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica. 2008; 93: 1837-1842.","DOI":"10.3324\/haematol.13273"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Lazarus HM, Carreras J, Boudreau C <i>et al.<\/i> Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood &amp; Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008; 14: 1323-1333.","DOI":"10.1016\/j.bbmt.2008.09.008"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Andorsky DJ, Cohen M, Naeim A, Pinter-Brown L. Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. Bone Marrow Transplant. 2011; 46: 1219-1225.","DOI":"10.1038\/bmt.2010.289"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Sehn LH, Herrera AF, Flowers CR <i>et al.<\/i> Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020; 38: 155-165.","DOI":"10.1200\/JCO.19.00172"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Terui Y, Rai S, Izutsu K <i>et al.<\/i> A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed\/refractory diffuse large B\u2010cell lymphoma. Cancer Sci. 2021; 112: 2845-2854.","DOI":"10.1111\/cas.14937"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Ohmachi K, Niitsu N, Uchida T <i>et al.<\/i> Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013; 31: 2103-2109.","DOI":"10.1200\/JCO.2012.46.5203"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Yamauchi N, Maruyama D. Current development of chimeric antigen receptor T\u2010cell therapy for diffuse large B\u2010cell lymphoma and high\u2010grade B\u2010cell lymphoma. Eur J Haematol. 2024; 112: 662-677.","DOI":"10.1111\/ejh.14166"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Abramson JS, Palomba ML, Gordon LI <i>et al.<\/i> Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396: 839-852.","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Neelapu SS, Locke FL, Bartlett NL <i>et al.<\/i> Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017; 377: 2531-2544.","DOI":"10.1056\/NEJMoa1707447"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Schuster SJ, Bishop MR, Tam CS <i>et al.<\/i> Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019; 380: 45-56.","DOI":"10.1056\/NEJMoa1804980"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Thieblemont C, Phillips T, Ghesquieres H <i>et al.<\/i> Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II Trial. J Clin Oncol. 2023; 41: 2238-2247.","DOI":"10.1200\/JCO.22.01725"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Izutsu K, Kumode T, Yuda J <i>et al.<\/i> Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed\/refractory diffuse large B\u2010cell lymphoma. Cancer Sci. 2023; 114: 4643-4653.","DOI":"10.1111\/cas.15996"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Shouse G, Danilov AV, Artz A. CAR T-cell therapy in the older person: indications and risks. Curr Oncol Rep. 2022; 24: 1189-1199.","DOI":"10.1007\/s11912-022-01272-6"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Chihara D, Liao L, Tkacz J <i>et al.<\/i> Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2023; 142: 1047-1055.","DOI":"10.1182\/blood.2023020197"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Crump M, Neelapu SS, Farooq U <i>et al.<\/i> Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130: 1800-1808.","DOI":"10.1182\/blood-2017-03-769620"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Suzuki T, Maruyama D, Miyagi-Maeshima A <i>et al.<\/i> Clinicopathological analysis of primary refractory diffuse large B\u2010cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. Cancer Med. 2021; 10: 5101-5109.","DOI":"10.1002\/cam4.4062"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Nowakowski GS, Chiappella A, Gascoyne RD <i>et al.<\/i> ROBUST: A phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021; 39: 1317-1328.","DOI":"10.1200\/JCO.20.01366"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Nowakowski GS, Hong F, Scott DW <i>et al.<\/i> Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412. J Clin Oncol. 2021; 39: 1329-1338.","DOI":"10.1200\/JCO.20.01375"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Davies A, Cummin TE, Barrans S <i>et al.<\/i> Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019; 20: 649-662.","DOI":"10.1016\/S1470-2045(18)30935-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Younes A, Sehn LH, Johnson P <i>et al.<\/i> Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019; 37: 1285-1295.","DOI":"10.1200\/JCO.18.02403"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Tilly H, Morschhauser F, Sehn LH <i>et al.<\/i> Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022; 386: 351-363.","DOI":"10.1056\/NEJMoa2115304"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Cheson BD, Nowakowski G, Salles G. Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer J. 2021; 11: 68.","DOI":"10.1038\/s41408-021-00456-w"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Yagi Y, Kanemasa Y, Sasaki Y <i>et al.<\/i> Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma. Ann Hematol. 2023; 102: 1485-1500.","DOI":"10.1007\/s00277-023-05233-2"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/1\/65_24064\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T04:49:22Z","timestamp":1743223762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/1\/65_24064\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.24064","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"type":"print","value":"1346-4280"},{"type":"electronic","value":"1880-9952"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"24064"}}